Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 12, Décembre 2013
Page(s) 1105 - 1110
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20132912013
Publié en ligne 20 décembre 2013
  1. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009 ; 72 : 1976–1983. [CrossRef] [PubMed]
  2. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002 ; 360 : 2018–2025. [CrossRef] [PubMed]
  3. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997 ; 62 : 112–118. [CrossRef] [PubMed]
  4. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997 ; 244 : 153–159. [CrossRef] [PubMed]
  5. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354 : 899–910. [CrossRef] [PubMed]
  6. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010 ; 362 : 387–401. [CrossRef] [PubMed]
  7. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011 ; 365 : 1293–1303. [CrossRef] [PubMed]
  8. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012 ; 367 : 1098–1107. [CrossRef] [PubMed]
  9. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012 ; 366 : 1000–1009. [CrossRef] [PubMed]
  10. Papeix C, Lubetzki C. Anticorps monoclonaux dans la sclérose en plaques. Med Sci (Paris) 2009 ; 25 : 1113–1115. [CrossRef] [EDP Sciences] [PubMed]
  11. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012 ; 380 : 1819–1828. [CrossRef] [PubMed]
  12. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011 ; 378 : 1779–1787. [CrossRef] [PubMed]
  13. Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 2012 ; 167 : 1035–1047. [CrossRef] [PubMed]
  14. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993 ; 259 : 1321–1324. [CrossRef] [PubMed]
  15. Van der Aa A, Hellings N, Medaer R, et al. T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin Exp Immunol 2003 ; 131 : 155–168. [PubMed]
  16. Mannie MD, Blanchfield JL, Islam SM, Abbott DJ., Cytokine-neuroantigenfusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis. Front Immunol 2012 ; 3 : 255. [CrossRef] [PubMed]
  17. Kaushansky N, Kerlero de Rosbo N, Zilkha-Falb R, et al. Multi-epitope-targeted immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides. PLoS One 2011 ; 6 : e27860. [CrossRef] [PubMed]
  18. Billetta R, Ghahramani N, Morrow O, et al. Epitope-specific immune tolerization ameliorates experimental autoimmune encephalomyelitis. Clin Immunol 2012 ; 145 : 94–101. [CrossRef] [PubMed]
  19. Perron H, Garson JA, Bedin F, et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The collaborative research group on multiple sclerosis. Proc Natl Acad Sci USA 1997 ; 94 : 7583–7588. [CrossRef]
  20. Curtin F, Lang AB, Perron H, et al. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther 2012 ; 34 : 2268–2278. [CrossRef] [PubMed]
  21. Lubetzki C. Sclérose en plaques : quelles possibilités de régénération ? Bull Acad Natl Med 2008 ; 192 : 495–506. [PubMed]
  22. Lubetzki C, Williams A, Stankoff B. Promoting repair in multiple sclerosis: problems and prospects. Curr Opin Neurol 2005 ; 18 : 237–244. [CrossRef] [PubMed]
  23. Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009 ; 65 : 304–315. [CrossRef] [PubMed]
  24. Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008 ; 29 : 558–565. [CrossRef] [PubMed]
  25. Papeix C, Lubetzki C. Anticorps monoclonaux dans la sclérose en plaques. Med Sci (Paris) 2009 ; 25 : 1113–1115. [CrossRef] [EDP Sciences] [PubMed]
  26. Cuvillier O. Les récepteurs de la sphingosine 1-phosphate. Med Sci (Paris) 2012 ; 28 : 951–957. [CrossRef] [EDP Sciences] [PubMed]
  27. Sibilia J. Protéine de fusion ou anticorps monoclonal. Med Sci (Paris) 2009 ; 25 : 1033–1038. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.